CYP2C9*1BPromoter Polymorphisms, in Linkage withCYP2C19*2, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose-Reference-Cited by-同舟云学术

CYP2C9*1BPromoter Polymorphisms, in Linkage withCYP2C19*2, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose

Published:2009-10-23 Issue:2 Volume:332 Page:599-611
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Chaudhry Amarjit S.,Urban Thomas J.,Lamba Jatinder K.,Birnbaum Angela K.,Remmel Rory P.,Subramanian Murali,Strom Stephen,You Joyce H.,Kasperaviciute Dalia,Catarino Claudia B.,Radtke Rodney A.,Sisodiya Sanjay M.,Goldstein David B.,Schuetz Erin G.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference35 articles.

1. Activation of Human CYP2C9 Promoter and Regulation by CAR and PXR in Mouse Liver

2. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients

3. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

4. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite;Bajpai;Drug Metab Dispos,1996

5. Allelic and functional variability of cytochrome P4502C9;Bhasker;Pharmacogenetics,1997

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An analysis of the Michaelis-Menten pharmacokinetics of phenytoin in epileptic Indonesian adults;Pharmacy Education;2023-10-10

2. Pharmacogenetic variants of CYP2C9 and CYP2C19 associated with adverse reactions induced by antiepileptic drugs used in Peru;Pharmacia;2023-08-15

3. A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with VariousCYP2C9Genotypes under Different Cotreatments;Drug Metabolism and Disposition;2022-11-15

4. Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury;Expert Opinion on Drug Metabolism & Toxicology;2022-08-03

5. Pharmacokinetic Modeling of Warfarin ІI – Model-Based Analysis of Warfarin Metabolites after Warfarin Administered Either Alone or Together with Fluconazole or Rifampin;Drug Metabolism and Disposition;2022-07-07